Text Size

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00947115
First received: July 16, 2009
Last updated: February 21, 2013
Last verified: February 2013
History of Changes
Results First Received: February 10, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Human Papillomavirus Infection
Interventions: Procedure: Blood sampling
Procedure: Cervico-vaginal secretion (CVS) samples

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Out of the 666 subjects who received at least one vaccine dose in primary study (NCT00196937), one subject was erroneously invited for the Year 5 visit of this study, but was not eligible and was excluded from all Year 5 analyses. Further, a total of 158 subjects missed the Year 5 visit. Therefore, a total of 507 subjects are reported for year 5.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Some subjects who came for the Year 5 timepoint did not show up for the Year 6 or Year 7 timepoints, while not all subjects who entered the Year 6 or 7 timepoints were present for the Year 5 timepoint.

Reporting Groups
  Description
Cervarix 15-25 Years Group Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
Cervarix 26-45 Years Group Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
Cervarix 46-55 Years Group Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)

Participant Flow for 3 periods

 Period 1:   Year 5 (Month 60)
    Cervarix 15-25 Years Group     Cervarix 26-45 Years Group     Cervarix 46-55 Years Group  
STARTED     153     184     170  
COMPLETED     153     184     170  
NOT COMPLETED     0     0     0  

Period 2:   Year 6 (Month 72)
    Cervarix 15-25 Years Group     Cervarix 26-45 Years Group     Cervarix 46-55 Years Group  
STARTED     147     177     164  
COMPLETED     147     177     164  
NOT COMPLETED     0     0     0  

Period 3:   Year 7 (Month 84)
    Cervarix 15-25 Years Group     Cervarix 26-45 Years Group     Cervarix 46-55 Years Group  
STARTED     149     165     160  
COMPLETED     149     165     160  
NOT COMPLETED     0     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Cervarix 15-25 Years Group Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
Cervarix 26-45 Years Group Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
Cervarix 46-55 Years Group Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
Total Total of all reporting groups

Baseline Measures
    Cervarix 15-25 Years Group     Cervarix 26-45 Years Group     Cervarix 46-55 Years Group     Total  
Number of Participants  
[units: participants]
 		  153     184     170     507  
Age  
[units: Years]
Mean ± Standard Deviation 		  25.7  ± 2.82     41.0  ± 6.02     54.4  ± 3.15     40.9  ± 12.22  
Gender  
[units: subjects]
 		       
Female     153     184     170     507  
Male     0     0     0     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum   [ Time Frame: At Year 5 and 6 ]
  Show Outcome Measure 1

2.  Primary:   Number of Seroconverted Subjects.   [ Time Frame: At Year 5 and Year 6 ]
  Show Outcome Measure 2

3.  Secondary:   Total Immunoglobulin G (IgG) Antibody Titers in Serum   [ Time Frame: At Year 5 and Year 6 ]
  Show Outcome Measure 3

4.  Secondary:   Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)   [ Time Frame: At Year 5 and Year 6 ]
  Show Outcome Measure 4

5.  Secondary:   Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS   [ Time Frame: At Year 5 and Year 6 ]
  Show Outcome Measure 5

6.  Secondary:   Total Immunoglobulin G (IgG) Antibody Titers in Serum   [ Time Frame: At Year 5 and Year 6 ]
  Show Outcome Measure 6

7.  Secondary:   Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).   [ Time Frame: From Month 48 in primary study (NCT00196937) up to Month 60 (Year 5) ]
  Show Outcome Measure 7

8.  Secondary:   Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).   [ Time Frame: From the Month 60 (Year 5) visit until the Month 72 (Year 6) visit ]
  Show Outcome Measure 8

9.  Secondary:   Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).   [ Time Frame: From Month 72 (Year 6) visit to Month 84 (Year 7) visit ]
  Show Outcome Measure 9

10.  Secondary:   Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).   [ Time Frame: From Year 0 up to Year 7 ]
  Show Outcome Measure 10

11.  Primary:   Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum   [ Time Frame: At Years 7, 8, 9, 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No

12.  Primary:   Number of Seroconverted Subjects.   [ Time Frame: At Years 7, 8, 9, 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No

13.  Secondary:   Total Immunoglobulin G (IgG) Antibody Titers in Serum   [ Time Frame: At Years 7, 8, 9, 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No

14.  Secondary:   Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)   [ Time Frame: At Years 7, 8, 9, 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No

15.  Secondary:   Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS   [ Time Frame: At Years 7, 8, 9, 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No

16.  Secondary:   Total Immunoglobulin G (IgG) Antibody Titers in Serum   [ Time Frame: At Years 7, 8, 9, 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No

17.  Secondary:   Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).   [ Time Frame: Until Year 10 ]
Results not yet posted.   Anticipated Posting Date:   01/2016   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


No publications provided


Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00947115     History of Changes
Other Study ID Numbers: 112772
Study First Received: July 16, 2009
Results First Received: February 10, 2011
Last Updated: February 21, 2013
Health Authority: Germany: Paul-Ehrlich-Institut